Resource Vault

This poster details the discovery and validation of fully human anti-ACVR2A antibodies for metabolic and musculoskeletal disorders . Overcoming high species homology via a specialized transgenic platform, it provides comprehensive data on pathway blockade, pharmacokinetics, and in vivo efficacy for improving body composition and muscle function.

This brochure introduces a specialized pharmacology platform for the preclinical evaluation of oligonucleotide therapeutics. It details in vivo humanized models and in vitro iPSC assays covering metabolic, neurological, and ophthalmic diseases. This resource provides essential validation strategies for researchers advancing RNA-based therapies toward IND filing.

The Cre-loxP Recombination System Guide is a practical manual for researchers utilizing conditional genetics. It covers fundamental principles, mouse model construction, breeding strategies, and genotyping. By addressing critical troubleshooting areas like tamoxifen induction and background leakiness, this guide helps scientists optimize in vivo gene editing.

This poster details a sodium iodate-induced mouse model for studying dry age-related macular degeneration (AMD). Since dry AMD accounts for 90% of cases and features retinal pigment epithelial (RPE) cell apoptosis, this model accurately simulates advanced-stage pathology via oxidative stress. Furthermore, the poster demonstrates the model's utility by evaluating the therapeutic efficacy of Pegcetacoplan.

The Cyagen Cell Line Catalog provides a comprehensive directory of wild-type and genetically modified cell lines to support biomedical research. Spanning eight categories—including a diverse portfolio of iPSC models —this resource offers detailed specifications for hundreds of models. Researchers can efficiently identify optimal in vitro tools to advance studies in oncology, neurodegeneration, and metabolic diseases.

This report analyzes selected AACR 2026 preclinical abstracts to map oncology R&D momentum across targets, indications, and therapeutic modalities. Key signals include continued ADC differentiation, rapid growth of molecular glues and degraders, rising AI-enabled oncology research, and evolving strategies in IO combinations and solid tumor CAR-T. The analysis highlights competitive hotspots such as PD-1/PD-L1, HER2, TROP2, KRAS, PRMT5, EGFR/c-Met, and NSCLC.